Laily Shofiyah
Research Subjects
Laily Shofiyah has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Eti Poncorini Pamungkasari
Universitas Sebelas Maret
1 shared publication - Ida Nurwati
Universitas Sebelas Maret
1 shared publication - Paramasari Dirgahayu
Universitas Sebelas Maret, Surakarta, Indonesia
1 shared publication - Ratih Puspita Febrinasari
Department of pharmacology, Faculty of Medicine, Universitas Sebelas Maret
1 shared publication - Risya Cilmiaty
Universitas Sebelas Maret, Surakarta, Indonesia
1 shared publication - Tonang Dwi Ardyanto
Sebelas Maret University, Sebelas Maret University Hospital, Indonesia
1 shared publication
Latest Publications
- Open Access
- 1 March 2026
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 14 (2)
Network pharmacology and molecular docking approach to identify the mechanisms and molecular targets of Allium ascalonicum L. extract against atherosclerosis
Context: Atherosclerosis remains a leading cause of mortality globally, and current therapeutic strategies are often insufficient. Allium ascalonicum L. (shallot) has demonstrated cardioprotective effects, but its molecular mechanisms remain inadequately defined. Aims: To elucidate the molecular mechanisms and potential targets of A. ascalonicum extract in the prevention and treatment of atherosclerosis. Methods: A network pharmacology and molecular docking approach was employed to investigate the interactions between key bioactive compounds (kaempferol, quercetin, quercetin 3-O-alpha-L-rhamnoside, and allicin) and atherosclerosis-associated proteins. Results: Target prediction identified 1,644 atherosclerosis-related proteins interacting with A. ascalonicum compounds. Among these, Nrf2 was highlighted as a primary target involved in lipid metabolism, oxidative stress, and inflammation. Molecular docking revealed strong binding affinities between Nrf2 regulators (KEAP1) and bioactive compounds, particularly quercetin 3-O-alpha-L-rhamnoside. Conclusions: The findings suggest that A. ascalonicum may serve as a potential anti-atherosclerotic agent through modulation of the KEAP1-Nrf2 pathway. These results warrant further experimental validation.
- 1 March 2026
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 14 (2)
Open AccessNetwork pharmacology and molecular docking approach to identify the mechanisms and molecular targets of Allium ascalonicum L. extract against atherosclerosis
Context: Atherosclerosis remains a leading cause of mortality globally, and current therapeutic strategies are often insufficient. Allium ascalonicum L. (shallot) has demonstrated cardioprotective effects, but its molecular mechanisms remain inadequately defined. Aims: To elucidate the molecular mechanisms and potential targets of A. ascalonicum extract in the prevention and treatment of atherosclerosis. Methods: A network pharmacology and molecular docking approach was employed to investigate the interactions between key bioactive compounds (kaempferol, quercetin, quercetin 3-O-alpha-L-rhamnoside, and allicin) and atherosclerosis-associated proteins. Results: Target prediction identified 1,644 atherosclerosis-related proteins interacting with A. ascalonicum compounds. Among these, Nrf2 was highlighted as a primary target involved in lipid metabolism, oxidative stress, and inflammation. Molecular docking revealed strong binding affinities between Nrf2 regulators (KEAP1) and bioactive compounds, particularly quercetin 3-O-alpha-L-rhamnoside. Conclusions: The findings suggest that A. ascalonicum may serve as a potential anti-atherosclerotic agent through modulation of the KEAP1-Nrf2 pathway. These results warrant further experimental validation.